Details: pack, label wording, sources, registration
Atropine Pharmex 10 mg/ml (1%), Eye drops
eye drops 5 ml, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
Adjunctive therapeutic cycloplegia/mydriasis for painful miosis and ciliary spasm associated with corneal disease or anterior uveitis
6.4/10
Situational / acceptable
Details →
vetman assessment
Atropine Pharmex
×
10 mg/ml (1%), eye drops 5 ml, human medicine
Assessed clinical scope Dog · Adjunctive therapeutic cycloplegia/mydriasis for painful miosis and ciliary spasm associated with corneal disease or anterior uveitis · Into the eye
Care setting Veterinary ophthalmic treatment after examination, with case-specific frequency, minimum exposure and IOP/tear/corneal reassessment.
vetman score
6.4/10
Situational / acceptable
Evidence confidence: Medium
Georgia: Yes, human · № რ-037377 · Verified on 16 Oct 2026
Off-label use
An established off-label therapeutic role in a transparent 1% human product, useful for selected painful miosis/ciliary spasm with ophthalmic diagnosis and monitoring; exact-product veterinary outcomes and frequency remain unestablished.
Regulatory and scientific credibility 6.5/10
The exact 10 mg/ml 5 ml presentation and Pharmex manufacturing link are current in Ukrainian and Georgian registers, with an accessible exact instruction transcription and strong same-form regulatory controls. The official Ukrainian public name is generic, the instruction copy is secondary, and the exact product has no veterinary authorisation or target-animal dossier.
Clinical efficacy 7.0/10
Current veterinary consensus supports atropine 1% for miosis, painful reflex ciliary spasm and blood-aqueous-barrier stabilisation in corneal disease/anterior uveitis. Direct canine pharmacodynamics support biological activity, but exact-product diseased-eye comparative outcomes and one universal regimen are absent.
Safety and tolerability 5.5/10
One-drop canine studies document an early IOP rise, and repeated daily exposure can suppress tear production beyond treatment. Systemic antimuscarinic absorption, glaucoma, corneal-surface compromise and prolonged effects require selection, minimum exposure and monitoring; exact-product veterinary safety is unstudied.
Clinical practicality 7.0/10
A 5 ml dropper and 14-day in-use period can support a short ophthalmic course, but frequency is case-specific and continuing care requires restraint, IOP/tear reassessment, punctal occlusion and contamination control.
Full-course cost-effectiveness -
A current Georgian exact-pack price and role-specific course/procedure cost were not verified; price is excluded from the denominator.
Important safety and use flags
Human medicine. Every canine/feline use of this exact 5 ml presentation is off-label; current Ukrainian/Georgian human registration does not make it veterinary-authorised. Do not use atropine 1% as the routine default for lens/fundus dilation. Its effect can last 24 hours to 7 days or longer; current veterinary consensus prefers short-acting tropicamide for that task. Exclude glaucoma and clinically important IOP elevation before use; monitor when exposure continues. A one-drop healthy-dog study showed an early mean IOP rise. Assess the cornea and baseline tear production. Repeated daily 1% atropine reduced canine tearing bilaterally and recovery remained incomplete five weeks after the last dose. Topical does not mean local only. Apply nasolacrimal occlusion and wipe excess to reduce swallowing/systemic absorption; monitor for tachycardia, dry mucosae, GI hypomotility, urinary retention, agitation, weakness or hyperthermia. Stop and reassess marked or persistent stinging, blepharospasm, conjunctival inflammation, keratitis or hypersensitivity. Sodium metabisulfite (E223) may cause allergic reactions. Review all medicines. Other antimuscarinics can add systemic toxicity; atropine opposes cholinergic miotics/antiglaucoma drugs such as pilocarpine and may complicate pressure control. Separate other ophthalmic medicines by at least 15 minutes. Do not touch the dropper to the eye, lids or surfaces, and do not share one bottle between animals. Store at no more than 25°C in the original pack and discard 14 days after opening. Do not extend the in-use period from another atropine product with different preservatives or packaging. Exact-product safety in pregnancy, lactation, neonates and very young animals is not established. Record an individual benefit-risk decision and use the minimum justified exposure. Assessment sources +
Close
Dog
Routine diagnostic mydriasis for examination of the lens and fundus
5.1/10
Weak evidence support
Details →
vetman assessment
Atropine Pharmex
×
10 mg/ml (1%), eye drops 5 ml, human medicine
Assessed clinical scope Dog · Routine diagnostic mydriasis for examination of the lens and fundus · Into the eye
Care setting Clinic-administered diagnostic use assessed against shorter-acting tropicamide, with ocular examination and post-dose counselling/observation.
vetman score
5.1/10
Weak evidence support
Evidence confidence: Medium
Georgia: Yes, human · № რ-037377 · Verified on 16 Oct 2026
Off-label use
It dilates the pupil, but its prolonged action and safety burden make it a weak routine lens/fundus diagnostic choice when short-acting tropicamide is available.
Regulatory and scientific credibility 6.5/10
The exact 10 mg/ml 5 ml presentation and Pharmex manufacturing link are current in Ukrainian and Georgian registers, with an accessible exact instruction transcription and strong same-form regulatory controls. The official Ukrainian public name is generic, the instruction copy is secondary, and the exact product has no veterinary authorisation or target-animal dossier.
Clinical efficacy 5.0/10
Atropine reliably dilates and cyclopleges, but current veterinary consensus explicitly advises against it for routine lens/fundus dilation because a shorter-acting agent is better matched to that task; prolonged effect is not added diagnostic benefit.
Safety and tolerability 5.5/10
One-drop canine studies document an early IOP rise, and repeated daily exposure can suppress tear production beyond treatment. Systemic antimuscarinic absorption, glaucoma, corneal-surface compromise and prolonged effects require selection, minimum exposure and monitoring; exact-product veterinary safety is unstudied.
Clinical practicality 2.5/10
Instillation is simple, but 24-hour-to-7-day-or-longer dilation is disproportionate for a routine lens/fundus examination and complicates recovery, owner counselling and repeat assessment compared with short-acting tropicamide.
Full-course cost-effectiveness -
A current Georgian exact-pack price and role-specific course/procedure cost were not verified; price is excluded from the denominator.
Important safety and use flags
Human medicine. Every canine/feline use of this exact 5 ml presentation is off-label; current Ukrainian/Georgian human registration does not make it veterinary-authorised. Do not use atropine 1% as the routine default for lens/fundus dilation. Its effect can last 24 hours to 7 days or longer; current veterinary consensus prefers short-acting tropicamide for that task. Exclude glaucoma and clinically important IOP elevation before use; monitor when exposure continues. A one-drop healthy-dog study showed an early mean IOP rise. Assess the cornea and baseline tear production. Repeated daily 1% atropine reduced canine tearing bilaterally and recovery remained incomplete five weeks after the last dose. Topical does not mean local only. Apply nasolacrimal occlusion and wipe excess to reduce swallowing/systemic absorption; monitor for tachycardia, dry mucosae, GI hypomotility, urinary retention, agitation, weakness or hyperthermia. Stop and reassess marked or persistent stinging, blepharospasm, conjunctival inflammation, keratitis or hypersensitivity. Sodium metabisulfite (E223) may cause allergic reactions. Review all medicines. Other antimuscarinics can add systemic toxicity; atropine opposes cholinergic miotics/antiglaucoma drugs such as pilocarpine and may complicate pressure control. Separate other ophthalmic medicines by at least 15 minutes. Do not touch the dropper to the eye, lids or surfaces, and do not share one bottle between animals. Store at no more than 25°C in the original pack and discard 14 days after opening. Do not extend the in-use period from another atropine product with different preservatives or packaging. Exact-product safety in pregnancy, lactation, neonates and very young animals is not established. Record an individual benefit-risk decision and use the minimum justified exposure. Assessment sources +
Close
Cat
Adjunctive therapeutic cycloplegia/mydriasis for painful miosis and ciliary spasm associated with corneal disease or anterior uveitis
5.7/10
Weak evidence support
Details →
vetman assessment
Atropine Pharmex
×
10 mg/ml (1%), eye drops 5 ml, human medicine
Assessed clinical scope Cat · Adjunctive therapeutic cycloplegia/mydriasis for painful miosis and ciliary spasm associated with corneal disease or anterior uveitis · Into the eye
Care setting Veterinary ophthalmic treatment after examination, with case-specific frequency, minimum exposure and IOP/tear/corneal reassessment.
vetman score
5.7/10
Weak evidence support
Evidence confidence: Medium
Georgia: Yes, human · № რ-037377 · Verified on 16 Oct 2026
Off-label use
A plausible established feline therapeutic role, but direct 1% tolerance and IOP findings materially narrow its use. Select patients carefully, minimise exposure and monitor rather than treating it as a routine benign eye drop.
Regulatory and scientific credibility 6.5/10
The exact 10 mg/ml 5 ml presentation and Pharmex manufacturing link are current in Ukrainian and Georgian registers, with an accessible exact instruction transcription and strong same-form regulatory controls. The official Ukrainian public name is generic, the instruction copy is secondary, and the exact product has no veterinary authorisation or target-animal dossier.
Clinical efficacy 6.5/10
Veterinary consensus supports therapeutic cycloplegia, pain relief and synechiae prevention in feline anterior uveitis/corneal disease, but exact-product diseased-eye outcomes are absent and newer direct data show that 1% is less tolerable than 0.1% in healthy cats.
Safety and tolerability 4.5/10
Direct 1% feline studies show reproducible IOP elevation, marked immediate discomfort and prolonged pupil non-responsiveness. Bitter nasolacrimal drainage can trigger salivation/vomiting, systemic absorption remains possible, and exact-product diseased-cat safety is unstudied.
Clinical practicality 5.0/10
A dropper bottle is simple, but feline bitter-taste distress, restraint, baseline/follow-up tonometry, minimum exposure, prolonged effects and 14-day discard create meaningful clinical burden.
Full-course cost-effectiveness -
A current Georgian exact-pack price and role-specific course/procedure cost were not verified; price is excluded from the denominator.
Important safety and use flags
Human medicine. Every canine/feline use of this exact 5 ml presentation is off-label; current Ukrainian/Georgian human registration does not make it veterinary-authorised. Do not use atropine 1% as the routine default for lens/fundus dilation. Its effect can last 24 hours to 7 days or longer; current veterinary consensus prefers short-acting tropicamide for that task. Exclude glaucoma and clinically important IOP elevation before use; monitor during treatment. One-drop feline 1% studies show significant IOP elevation and prolonged pupil non-responsiveness. Assess the cornea, tear film and ocular surface before treatment. Direct short feline exposure did not lower STT at 8 hours, but repeated diseased-eye exposure and exact-product surface safety are unestablished. Topical does not mean local only. Apply nasolacrimal occlusion and wipe excess to reduce swallowing/systemic absorption; monitor for tachycardia, dry mucosae, GI hypomotility, urinary retention, agitation, weakness or hyperthermia. The solution is bitter after nasolacrimal drainage and 1% caused marked immediate discomfort in a direct feline study. Hypersalivation or vomiting can occur; ointment or lower-concentration alternatives may be better tolerated when clinically appropriate. Review all medicines. Other antimuscarinics can add systemic toxicity; atropine opposes cholinergic miotics/antiglaucoma drugs such as pilocarpine and may complicate pressure control. Separate other ophthalmic medicines by at least 15 minutes. Do not touch the dropper to the eye, lids or surfaces, and do not share one bottle between animals. Store at no more than 25°C in the original pack and discard 14 days after opening. Do not extend the in-use period from another atropine product with different preservatives or packaging. Exact-product safety in pregnancy, lactation, neonates and very young animals is not established. Record an individual benefit-risk decision and use the minimum justified exposure. Assessment sources +
Close
Cat
Routine diagnostic mydriasis for examination of the lens and fundus
4.6/10
Weak evidence support
Details →
vetman assessment
Atropine Pharmex
×
10 mg/ml (1%), eye drops 5 ml, human medicine
Assessed clinical scope Cat · Routine diagnostic mydriasis for examination of the lens and fundus · Into the eye
Care setting Clinic-administered diagnostic use assessed against shorter-acting tropicamide, with ocular examination and post-dose counselling/observation.
vetman score
4.6/10
Weak evidence support
Evidence confidence: Medium
Georgia: Yes, human · № რ-037377 · Verified on 16 Oct 2026
Off-label use
Reliable dilation does not offset marked feline discomfort, IOP elevation and prolonged pupil non-responsiveness; it is a weak routine diagnostic default.
Regulatory and scientific credibility 6.5/10
The exact 10 mg/ml 5 ml presentation and Pharmex manufacturing link are current in Ukrainian and Georgian registers, with an accessible exact instruction transcription and strong same-form regulatory controls. The official Ukrainian public name is generic, the instruction copy is secondary, and the exact product has no veterinary authorisation or target-animal dossier.
Clinical efficacy 4.5/10
One-drop feline studies confirm marked dilation, but current veterinary consensus advises against routine lens/fundus use and direct feline data show prolonged pupil non-responsiveness; reliable dilation does not make 1% atropine a good routine diagnostic default.
Safety and tolerability 4.5/10
Direct 1% feline studies show reproducible IOP elevation, marked immediate discomfort and prolonged pupil non-responsiveness. Bitter nasolacrimal drainage can trigger salivation/vomiting, systemic absorption remains possible, and exact-product diseased-cat safety is unstudied.
Clinical practicality 2.0/10
Instillation is simple, but marked immediate discomfort, IOP monitoring and a median 47.5 hours of pupil non-responsiveness in a direct 1% study make this particularly impractical for routine feline lens/fundus examination.
Full-course cost-effectiveness -
A current Georgian exact-pack price and role-specific course/procedure cost were not verified; price is excluded from the denominator.
Important safety and use flags
Human medicine. Every canine/feline use of this exact 5 ml presentation is off-label; current Ukrainian/Georgian human registration does not make it veterinary-authorised. Do not use atropine 1% as the routine default for lens/fundus dilation. Its effect can last 24 hours to 7 days or longer; current veterinary consensus prefers short-acting tropicamide for that task. Exclude glaucoma and clinically important IOP elevation before use; monitor during treatment. One-drop feline 1% studies show significant IOP elevation and prolonged pupil non-responsiveness. Assess the cornea, tear film and ocular surface before treatment. Direct short feline exposure did not lower STT at 8 hours, but repeated diseased-eye exposure and exact-product surface safety are unestablished. Topical does not mean local only. Apply nasolacrimal occlusion and wipe excess to reduce swallowing/systemic absorption; monitor for tachycardia, dry mucosae, GI hypomotility, urinary retention, agitation, weakness or hyperthermia. The solution is bitter after nasolacrimal drainage and 1% caused marked immediate discomfort in a direct feline study. Hypersalivation or vomiting can occur; ointment or lower-concentration alternatives may be better tolerated when clinically appropriate. Review all medicines. Other antimuscarinics can add systemic toxicity; atropine opposes cholinergic miotics/antiglaucoma drugs such as pilocarpine and may complicate pressure control. Separate other ophthalmic medicines by at least 15 minutes. Do not touch the dropper to the eye, lids or surfaces, and do not share one bottle between animals. Store at no more than 25°C in the original pack and discard 14 days after opening. Do not extend the in-use period from another atropine product with different preservatives or packaging. Exact-product safety in pregnancy, lactation, neonates and very young animals is not established. Record an individual benefit-risk decision and use the minimum justified exposure. Assessment sources +
Close
Administration route
Into the eye
Registration
Georgia
Yes, human
In force until 21 Feb 2028
Human (Ministry of Health, RAMA)
In the register: ატროპინი ფარმექსი 10 მგ/მლ (1%), თვალის წვეთები 5 მლ
№ რ-037377
Verified on: 16 Oct 2026
EU
No
UK
No
US
No
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Information not fully verified
All dog/cat use of this exact human product is off-label. Atropine 1% is primarily a therapeutic cycloplegic/mydriatic for painful reflex ciliary spasm, miosis and blood-aqueous-barrier disruption associated with corneal disease or anterior uveitis; it is not the routine choice for lens/fundus dilation because effects may last 24 hours to 7 days or longer. No exact-product veterinary frequency is established. Do not copy the human 1–2-drop, 2–6-times-daily schedule or turn one-drop healthy-animal studies into a universal treatment regimen.
